Dizocilpine and reduced body temperature do not prevent methamphetamine- induced neurotoxicity in the vervet monkey: [11C]WIN 35,428-positron emission tomography studies

Neuroscience Letters

Volumn 258, Issue 1, 1998, Pages 17-20

  Melega, William P ^a   Lacan, Goran ^a   Harvey, Dennis C ^a   Huang, Sung Cheng ^a   Phelps, Michael E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dizocilpine; Hyperthermia; Methamphetamine; Neurotoxicity; Positron emission tomography; WIN 35,428

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARBON 11; COCAINE DERIVATIVE; DIZOCILPINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; INDUCED HYPOTHERMIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONKEY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; CARBON RADIOISOTOPES; CARRIER PROTEINS; CERCOPITHECUS AETHIOPS; COCAINE; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HYPOTHERMIA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032509459     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00845-3     Document Type: Article

References (19)

1. [1] Ali, S.F., Newport, G.D., Holson, R.R., Slikker, W. and Bowyer, J.F., Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice, Brain Res., 658 (1994) 33-38.
2. [2] Bowyer, J.F. and Holson, R.R., Methamphetamine and amphetamine neurotoxicity. In L.W. Chang and R.S. Dyers (Eds.), Handbook of Neurotoxicology, Vol. 2, Marcel Dekker, New York, 1995, pp. 845-870.
3. [3] Bowyer, J.F. and Tank, W., The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum, J. Pharmacol. Exp. Ther., 260 (1992) 817-824.
4. 3H]WIN 35,428) in the monkey brain, Synapse, 6 (1990) 189-195.
5. [5] Cook, C.E., Jeffcoat, A.R., Hill, J.M., Pugh, D.E., Patetta, P.K., Sadler, B.M., White, W.R. and Perez-Reyes, M., Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride, Drug Metab. Dispos., 21 (1993) 717-723.
6. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease, Ann. Neurol., 34 (1993) 423-431.
7. [7] Fuller, R. and Hemrick-Luecke, S., Further studies on the long-term depletion of striatal dopamine in iprindole-treated rats by amphetamine, Neuropharmacology, 21 (1982) 433-438.
8. 3H-dopamine uptake, and 3H-PCP binding, Pharmacol. Biochem. Behav., 22 (1985) 731-735.
9. [9] Melega, W.P., Lacan, G., Stout, D.B., Huang, S.-C. and Phelps, M.E., Recovery of striatal dopamine function after acute amphetamine and methamphetamine-induced neurotoxicity in the vervet monkey, Brain Res., 766 (1997) 113-120.
10. 18F]fluoro-L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine, Behav. Brain Res., 84 (1997) 259-268.
11. [11] Meltzer, P.C., Liang, A.Y., Brownell, A.-L., Elmaleh, D.R. and Madras, B.K., Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging, J. Med. Chem., 36 (1993) 855-862.
12. 11C-CFT, Synapse, 24 (1996) 262-272.
13. [13] Patlak, C.S. and Blasberg, R.G., Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations, J. Cereb. Blood Flow Metab., 5 (1985) 584-590.
14. 11C]β-CFT in early Parkinson's Disease, Synapse, 21 (1995) 97-103.
15. 3/KF, Appl. Radiat. Isot., 46 (1995) 893-897.
16. [16] Seiden, L., Sabol, K. and Ricaurte, G., Amphetamine: effects on catecholamine systems and behavior, Annu. Rev. Pharmacol. Toxicol., 32 (1993) 639-677.
17. [17] Sonsalla, P.K., Riordan, D.E. and Heikkila, R.E., Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice, J. Pharmacol. Exp. Ther., 256 (1991) 506-512.
18. [18] Villemagne, V., Yuan, J., Wong, D., Dannals, R., Hatzidimitriou, G., Mathews, W., Ravert, H., Musachio, J., McCann, U. and Ricaurte, G., Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN 35,428 positron emission tomography studies and direct in vitro determinations, J. Neurosci., 18 (1998) 419-427.
19. [19] Woolverton, W.L., Ricaurte, G.A., Forno, L.S. and Seiden, L.S., Long-term effects of chronic methamphetamine administration in rhesus monkeys, Brain Res., 486 (1989) 73-78.